|

Ocrelizumab Clinical Trials

10 actively recruiting trials across 4 locations

Also known as: OCREVUS®, Ocrevus, RO4964913, RO4964913, Ocrevus, RO4964913; Ocrevus +1 more

Pipeline

Phase 2: 1Phase 3: 3Phase 4: 4

Top Sponsors

  • Hoffmann-La Roche4
  • University of California, San Francisco1
  • Novartis Pharmaceuticals1
  • National Institute of Allergy and Infectious Diseases (NIAID)1
  • Biogen1

Indications

  • Multiple Sclerosis10
  • Relapsing Multiple Sclerosis2
  • Multiple Sclerosis, Relapsing-Remitting2
  • Primary Progressive Multiple Sclerosis1
  • Relapsing-remitting Multiple Sclerosis (RRMS)1

Other6 trials

A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
Phase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
Phase 4
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Phase 2
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Phase 3
B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis
Phase 4

Scottsdale, Arizona1 trial

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Perseverance Research Center

Phase 3

San Francisco, California1 trial

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

University of California, San Francisco

Phase 4

New Haven, Connecticut1 trial

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Yale School of Medicine

Phase 4

Eden Prairie, Minnesota1 trial

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

OptumInsight

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.